drugset / Trial / NCT03871595

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

NCT03871595 ↗

Phase 1 Completed 14 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Investigate the relative bioavailability of BI 894416 as tablet formulation following a high-fat, high calorie breakfast (Test, T) compared with administration in the fasting state (Reference, R)

Timeline

Start
2019-03-20
Primary completion
2019-04-24
Completion
2019-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 894416 Unknown 30 mg Oral

Indications

No indication recorded.